Why Ionis Pharmaceuticals Stock Is Down 13% This Week
Shares of Ionis Pharmaceuticals (NASDAQ: IONS), a biotechnology company, have fallen around 13.6% since their closing price on Friday, Oct. 15, 2021. Investors were disappointed by phase 3 clinical trial results for tofersen, an experimental treatment for amyotrophic lateral sclerosis.
Treatment with tofersen was supposed to help reduce physical symptoms of ALS, a progressive neurodegenerative disorder that affects around 20,000 new U.S. patients annually. The experimental treatment was aimed at an even smaller subpopulation of ALS patients, those who have SOD1 mutations.
Image source: Getty Images.
Source Fool.com
